Radiolabeled NGR phage display peptide sequence for tumor targeting

Applied Radiation and Isotopes

Volumn 86, Issue , 2014, Pages 41-45

  Faintuch, B L ^a   Oliveira, E A ^a   Targino, R C ^b   Moro, A M ^b  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

Author keywords

Cyclic NGR peptide; Imaging; Radiolabeled

Indexed keywords

BIODISTRIBUTIONS; CONTRAST IMAGING; OVARIAN TUMOR; PEPTIDE SEQUENCES; RADIOLABELED; RENAL EXCRETION; TECHNETIUM 99; TUMOR TARGETING;

AMINO ACIDS; BIOLOGICAL ORGANS; IMAGING TECHNIQUES; PEPTIDES;

TUMORS;

DIAGNOSTIC AGENT; TECHNETIUM 99M; TECHNETIUM ASPARAGINYLGLYCYL ARGININE TC 99M; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG UPTAKE; HUMAN; HUMAN CELL; ISOTOPE LABELING; LUNG TUMOR; MOUSE; NONHUMAN; OVARY TUMOR; PHAGE DISPLAY; PRIORITY JOURNAL; TUMOR CELL; TUMOR MODEL; URINARY EXCRETION;

CYCLIC NGR PEPTIDE; IMAGING; RADIOLABELED;

ANIMALS; CELL LINE, TUMOR; FEMALE; LUNG NEOPLASMS; MALE; MICE; NEOPLASMS; OLIGOPEPTIDES; OVARIAN NEOPLASMS; PEPTIDE LIBRARY; RADIOPHARMACEUTICALS; TECHNETIUM;

EID: 84893126955     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2013.12.035     Document Type: Article

References (21)

1. Aina O.H., Marik J., Liu R., Lau D.H., Lam K.S. Identification of novel targeting peptides for human ovarian cancer cells using "one-bead one-compound"combinatorial libraries. Mol. Cancer Ther. 2005, 4:806-813.
2. 99mTc: a reflection on technetium core structures and a strategy for new chelate design. Nucl. Med. Biol. 2005, 32(1):1-20.
3. Berg C.D. The prostate, lung, colorectal and ovarian cancer screening trial: the prostate cancer screening results in context. Acta Oncol 2011, 50(1):12-17.
4. Boger-Megiddo I., Weiss N.S. Histologic subtypes and laterality of primary ovarian tumors. Gynecol. Oncol. 2005, 97:80-83.
5. Chen K., Ma W., Li G., Wang J., Yang W., Yap L.P., Hughes L.D., Park R., Conti P.S. Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression. Mol. Pharm. 2013, 10(1):417-427.
6. Corti A., Curnis F., Arap W., Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood 2008, 112(7):2628-2635.
7. Cramer D.W., Bast R.C., Berg C.D., Diamandis E.P., Godwin A.K., Hartge P., Lokshin A.E., Lu K.H., McIntosh M.W., Mor G., Patriotis C., Pinsky P.F., Thornquist M.D., Scholler N., Skates S.J., Sluss P.M., Srivastava S., Ward D.C., Zhang Z., Zhu C.S., Urban N. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev. Res. (Phila.) 2011, 4(3):365-374.
8. 99mTc-labeled bombesin analogues improves their pharmacokinetic properties. Nucl. Med. Biol. 2011, 38(7):997-1009.
9. Jiang W., Jin G., Ma D., Wang F., Fu T., Chen X., Chen X., Jia K., Marikar F.M., Hua Z. Modification of cyclic NGR tumor neovasculature homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth. PLoS One 2012, 7(5):e37132.
10. Krumpe L.R.H., Mori T. Potential of phage-displayed peptide library technology to identify functional targeting peptides. Expert Opin. Drug Discovery 2007, 2(4):525.
11. Ma W., Kang F., Wang Z., Yang W., Li G., Ma X., Li G., Chen K., Zhang Y., Wang J. (99m)Tc-labeled monomeric and dimeric NGR peptides for SPECT imaging of CD13 receptor in tumor-bearing mice. Amino Acids 2013, 44(5):1337-1345.
12. Oliveira E.A., Faintuch B.L., Núñez E.G., Moro A.M., Nanda P.K., Smith C.J. Radiotracers for different angiogenesis receptors in a melanoma model. Melanoma Res. 2012, 22(1):45-53.
13. Pasqualini R., Koivunen E., Kain R., Lahdenranta J., Sakamoto M., Stryhn A., Ashmun R.A., Shapiro L.H., Arap W., Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000, 60(3):722-727.
14. Sanli K.N., Mcguire M.J., Newgard C.B., Johnston S.A., Brown K.C. Peptide-mediated targeting of the islets of Langerhans. Diabetes 2005, 54(7):2103-2108.
15. Svensen N., Walton J.G.A., Bradley M. Peptides for cell-selective drug delivery. Trends Pharmacol. Sci. 2012, 33(4):186-192.
16. Thakkar A., Trinh T.B., Pei D. Global analysis of peptide cyclization efficiency. ACS Comb. Sci. 2013, 15(2):120-129.
17. van Hensbergen Y., Broxterman H.J., Rana S., Van Diest P.J., Duyndam M.C., Hoekman K., Pinedo H.M., Boven E. Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts. Clin. Cancer Res. 2004, 10:1180-1191.
18. Wang R.E., Niu Y., Wu H., Hu Y., Cai J. Development of NGR-based anti-cancer agents for targeted therapeutics and imaging. Anticancer Agents Med. Chem. 2012, 12:76-86.
19. Wei Y., Yin G., Yin H., Yan D., Ma C., Huang Z., Liao X., Yao Y., Chen X. Inhibiting effects of a cyclic peptide CNGRC on proliferation and migration of tumor cells in vitro. Int. J. Pept. Res. Ther. 2013, 19:163-173.
20. White C.J., Yudin A.K Contemporary strategies for peptide. Nat. Chem. 2011, 3:509-524.
21. 99mTc-labeled cyclic RGD peptides for noninvasive monitoring of tumor integrin αVβ3 expression. Mol. Imaging 2011, 10(5):386-397.